PDS Biotechnology Corporation (PDSB)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading PDS Biotechnology Corporation chart...

About the Company

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati

CEO

Frank Bedu-Addo

Exchange

NASDAQ

Website

https://www.pdsbiotech.com

$M

Total Revenue

26

Employees

$152M

Market Capitalization

-3.19

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PDSB News

The 3 Most Undervalued Biotech Stocks to Buy in March 2024

5d ago, source: Hosted on MSN

PDS Biotechnology Corporation (NASDAQ:PDSB) isn’t exactly a household name. It is an oncology firm on the fast track to ...

PDS Biotechnology Corp.

2mon ago, source: CNN

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer ...

PDS Biotech names Kirk V. Shepard as Chief Medical Officer

1mon ago, source: Hosted on MSN

Promising Phase 2 With Cash Issues That Might Be Worth The Risk PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotech ...

PDS Biotechnology Corporation (PDSB)

21d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

PDS Biotechnology Corp PDSB

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The 3 Most Undervalued Biotech Stocks to Buy in March 2024

5d ago, source: Business Insider

PDS Biotechnology Corporation (PDSB) PDS Biotechnology Corporation (NASDAQ:PDSB) isn’t exactly a household name. It is an oncology firm on the fast track to developing a successful and ...

PDS Biotechnology Corp.

2mon ago, source: CNN

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer ...

PDS Biotechnology Corp (PDSB)

11d ago, source: Investing

Investing.com - PDS Biotech (NASDAQ: PDSB) reported third quarter EPS of $-0.35, $0.10 better than the analyst estimate of $-0.45. Revenue for the quarter came in at $0.00 versus ...

PDS Biotechnology Corp (PDSB)

6d ago, source: Investing

Harami Cross 15 66 Mar 13, 2024 16:15 ...

PDS Biotechnology Corp (PDSB)

3d ago, source: Investing

All relevant comments and PDS Biotechnology Corp share chat regarding the PDSB NASDAQ share news are listed here in the PDSB forum. View and contribute to the PDSB share chat. Discuss PDS ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...